{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"semaglutide","verification":{"valid":true,"entries":3,"head":"e2c9583e9a7e4cea1133a0a25c701e08a92979b51a854413c7ffec2d6f6db4e5"},"count":3,"models":["grok-4.3"],"yield":{"passes":3,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok-4.3","passes":3,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:00:57.494Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"semaglutide","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a"},{"seq":1,"id":"k2","ts":"2026-06-29T17:01:16.648Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"0d5a1dd5bae4172a01dc4af7bbf0cf7590ab9c4a571a59dd01fffddc3b757e5a","hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d"},{"seq":2,"id":"k3","ts":"2026-06-29T17:01:41.374Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"cfbf5a3b4134bace32aa620bb5af70719e7f5688c47464cfd997f1008cbce05d","hash":"e2c9583e9a7e4cea1133a0a25c701e08a92979b51a854413c7ffec2d6f6db4e5"}]}